Go to the list of all blogs
Alicia's Avatar
published in Blogs
May 02, 2026
ExxonMobil (XOM) Q1 2026 Earnings: Adjusted Beat Highlights Upstream Strength

ExxonMobil (XOM) Q1 2026 Earnings: Adjusted Beat Highlights Upstream Strength

Key Takeaways

  • ExxonMobil reported GAAP net earnings of $4.2 billion, or $1.00 per diluted share (EPS), down from $7.7 billion, or $1.76 per share, in Q1 2025.
  • Adjusted earnings excluding identified items reached $4.9 billion, or $1.16 per share, surpassing consensus estimates around $1.00 to $1.07.
  • Net production hit 4.6 million barrels of oil equivalent per day (boe/d), with record output exceeding 900,000 gross barrels per day in Guyana.
  • Cash flow from operations was $8.7 billion, supporting $4.3 billion in dividends and $6.2 billion in capital expenditures (capex).
  • Company declared a Q2 dividend of $1.03 per share and plans $20 billion in share repurchases for 2026.
  • Sales and operating revenue totaled $83.2 billion, with total revenues and other income at $85.1 billion.

Q1 2026 Earnings in Context

ExxonMobil's (XOM) first-quarter 2026 results arrive against a backdrop of volatile oil prices, geopolitical tensions in the Middle East, and evolving global energy demand. As one of the largest integrated energy companies, its performance carries weight for the oil sector and shapes investor views on fossil fuels. From what I see, investors focus on production growth, refining margins, and capital discipline—particularly with major initiatives like the Stabroek Block in Guyana and low-carbon investments. These earnings demonstrate resilience in upstream operations, even with unfavorable timing effects from derivatives and inventory accounting, pointing to the company's skill in handling disruptions.

Breaking Down the Reported Results

ExxonMobil recorded GAAP earnings of $4.2 billion, or $1.00 per diluted share, down year-over-year mainly from lower commodity prices and $3.9 billion in unfavorable estimated timing effects related to mark-to-market impacts on crude oil derivatives and last-in, first-out (LIFO) inventory valuation. Excluding identified items—like $0.7 billion in hedge losses from Middle East disruptions—earnings came in at $4.9 billion, or $1.16 per share, topping analyst consensus of about $1.00 to $1.07. Stripping out timing effects entirely, underlying earnings hit $8.8 billion, or $2.09 per share, an increase from $7.6 billion in Q1 2025.

Sales and other operating revenue reached $83.2 billion, driving total revenues and other income to $85.1 billion, which beat expectations thanks to solid refining and trading in the Energy Products segment ($2.8 billion excluding items and timing). Upstream results were strong at 4.6 million boe/d, lifted by record Guyana production. I also checked production metrics using Tickeron’s AI Screener to compare XOM against peers. Cash flow from operations was $8.7 billion, yielding $2.7 billion in free cash flow after $6.2 billion in Q1 capex.

Market Reaction and What Investors Are Saying

After the May 1 release, XOM shares had a mixed initial response, slipping about 1.4% in pre-market to around $152 despite the adjusted EPS beat. While some reports mentioned a 1.5% premarket gain, overall sentiment leaned cautious due to the GAAP drop year-over-year and Middle East risks. Investors valued the upstream performance and cash flow but factored in softer refining margins and timing effects. Trading volume picked up, with attention turning to the company's proven model in volatile conditions.

Leveraging AI Tools in My Analysis

In my research workflow, Tickeron’s AI Screener has become a go-to for efficiently scanning stocks like XOM. It lets me filter thousands of stocks and ETFs by technical patterns, fundamentals, trends, volatility, and AI signals—customizing for industry, market cap, indicators, or performance. This helps spot trade ideas, breakouts, and opportunities faster than manual methods, and I've found it particularly useful for energy sector comparisons during earnings season.

Looking Ahead: Outlook and Factors to Watch

ExxonMobil stuck to its 2026 cash capex guidance of $27-29 billion, prioritizing high-return projects like Guyana expansions and Permian Basin growth. Plans include $20 billion in share repurchases assuming steady markets, plus advancing toward $20 billion in structural cost savings by 2030—now at $15.6 billion cumulative since 2019. I'm watching oil and gas prices closely, as stronger realizations bolstered Q1 upstream earnings; tools like Tickeron’s AI Trend Prediction Engine help track those trajectories.

Guyana's production ramp and U.S. LNG via Golden Pass (first train online) provide upside potential, though Middle East tensions may affect trading and hedges. Refining margins and Energy Products remain tied to crack spreads and demand. Longer-term, low-emission areas like carbon capture, hydrogen, and lithium hinge on policy and tech progress. Q2 results will shed light on volume growth and cost control, signaling sustained earnings through cycles.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: XOM

Contributor

Alicia's AvatarAlicia|Beginner

XOM in upward trend: price rose above 50-day moving average on July 17, 2026

XOM moved above its 50-day moving average on July 17, 2026 date and that indicates a change from a downward trend to an upward trend. In of 47 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The 10-day moving average for XOM crossed bullishly above the 50-day moving average on July 23, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where XOM advanced for three days, in of 370 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 316 cases where XOM Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for XOM moved out of overbought territory on July 31, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 43 similar instances where the indicator moved out of overbought territory. In of the 43 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 69 cases where XOM's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

The Momentum Indicator moved below the 0 level on August 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on XOM as a result. In of 92 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for XOM turned negative on August 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where XOM declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

XOM broke above its upper Bollinger Band on July 13, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 31, placing this stock better than average.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating outstanding price growth. XOM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.523) is normal, around the industry mean (2.244). P/E Ratio (26.067) is within average values for comparable stocks, (19.542). Projected Growth (PEG Ratio) (1.212) is also within normal values, averaging (1.259). Dividend Yield (0.026) settles around the average of (0.039) among similar stocks. P/S Ratio (2.025) is also within normal values, averaging (2.139).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

Notable companies

The most notable companies in this group are ExxonMobil Holdings Corporation (NYSE:XOM), Chevron Corp (NYSE:CVX), Petroleo Brasileiro Sa-Petrobras ADS (REP 1 Common Share) (NYSE:PBR), BP plc (NYSE:BP), Suncor Energy (NYSE:SU), YPF Sociedad Anonima (NYSE:YPF).

Industry description

Integrated oil companies are involved across nearly the entire oil value chain – from upstream operations like exploration and production, to downstream functions of refining and marketing. Exxon Mobil Corporation, Chevron Corporation and BP are major integrated oil companies. Their bottom lines’ response to crude oil prices could depend on the proportion of upstream vs. downstream businesses; for example, if a company has substantial downstream business, the adverse impact on their upstream business due to falling crude prices could be mitigated by benefits to its downstream business.

Market Cap

The average market capitalization across the Integrated Oil Industry is 115B. The market cap for tickers in the group ranges from 39.76K to 628.5B. XOM holds the highest valuation in this group at 628.5B. The lowest valued company is PGAS at 39.76K.

High and low price notable news

The average weekly price growth across all stocks in the Integrated Oil Industry was -3%. For the same Industry, the average monthly price growth was 10%, and the average quarterly price growth was 21%. DEC experienced the highest price growth at 3%, while SKYQ experienced the biggest fall at -9%.

Volume

The average weekly volume growth across all stocks in the Integrated Oil Industry was -4%. For the same stocks of the Industry, the average monthly volume growth was -29% and the average quarterly volume growth was -17%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 46
P/E Growth Rating: 55
Price Growth Rating: 42
SMR Rating: 62
Profit Risk Rating: 30
Seasonality Score: -30 (-100 ... +100)
View a ticker or compare two or three
XOM
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

a distributer of crude oil, natural gas and petroleum products

Industry IntegratedOil

Profile
Details
Industry
Integrated Oil
Address
22777 Springwoods Village Parkway
Phone
+1 972 940-6000
Employees
61500
Web
https://www.exxonmobil.com
Interact to see
Advertisement
Novartis (NVS) reports Q4/FY 2025 earnings on February 4, 2026, with consensus calling for ~$1.99 EPS on ~$13.7 billion in revenue. Sanofi (SNY) delivered strong FY 2025 results on January 29, reporting €43.6 billion in sales (+9.9% CER) and 15% business EPS growth.
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
MUFG is expected to report Q3 FY2026 EPS of about $0.30, broadly in line with its recent pattern of earnings beats.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
CME Group (CME): Q4 2025 earnings due February 4, 2026; consensus expects adjusted EPS $2.75 and revenue ~$1.6B. S&P Global (SPGI): Q4 2025 earnings due February 10, 2026; Q3 posted EPS $4.73 and 9% revenue growth, driven by Ratings, Indices, and Market Intelligence.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.